Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0470
-0.0060 (-11.32%)
Mar 26, 2026, 3:20 PM EST

PVCT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.340.620.560.99-
Revenue Growth (YoY)
-45.54%10.66%-43.61%--
Cost of Revenue
-1.961.72.312.52
Gross Profit
0.34-1.34-1.14-1.32-2.52
Selling, General & Admin
3.732.611.361.552.12
Research & Development
1.9----
Operating Expenses
5.632.611.361.552.12
Operating Income
-5.29-3.95-2.5-2.87-4.64
Interest Expense
-0.21-0.24-0.22-0.16-0.96
EBT Excluding Unusual Items
-5.51-4.19-2.71-3.03-5.6
Legal Settlements
--0.58-0.39-0.52-
Other Unusual Items
----0.06
Pretax Income
-5.51-4.76-3.1-3.55-5.54
Earnings From Continuing Operations
-5.51-4.76-3.1-3.55-5.54
Minority Interest in Earnings
0.07----
Net Income
-5.43-4.76-3.1-3.55-5.54
Net Income to Common
-5.43-4.76-3.1-3.55-5.54
Shares Outstanding (Basic)
420420420419408
Shares Outstanding (Diluted)
420420420419408
Shares Change (YoY)
0.11%0.07%0.01%2.76%3.81%
EPS (Basic)
-0.01-0.01-0.01-0.01-0.01
EPS (Diluted)
-0.01-0.01-0.01-0.01-0.01
Free Cash Flow
-3.33-3.28-2.57-3.04-1.01
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.00
Gross Margin
100.00%-216.87%-204.69%-133.60%-
Operating Margin
-1575.32%-639.43%-447.97%-290.12%-
Profit Margin
-1615.80%-771.65%-556.16%-359.41%-
Free Cash Flow Margin
-989.56%-532.15%-461.17%-307.52%-
EBITDA
-5.29-3.94-2.49-2.86-4.63
EBITDA Margin
----289.01%-
D&A For EBITDA
00.010.010.010.01
EBIT
-5.29-3.95-2.5-2.87-4.64
EBIT Margin
----290.12%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.